首页 › 胰腺癌 › 犹他州 › Salt Lake City
Salt Lake City UT 胰腺癌临床试验
15项针对 胰腺癌的研究正在 Salt Lake City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
招募中3 期
- University of Utah, Huntsman Cancer Institute, Salt Lake City
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
招募中3 期
- Investigative Site US053, Salt Lake City
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
招募中3 期
- Utah Cancer Specialists, Salt Lake City
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
招募中1/2 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
招募中观察性研究
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Pancreatic Cancer Early Detection Consortium
招募中观察性研究欢迎健康志愿者
- Huntsman Cancer Institute, Salt Lake City
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
招募中
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
招募中2 期
- Ohio State University-Telemedicine, Salt Lake City
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
招募中1/2 期
- Utah Cancer Specialists (site 203), Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Salt Lake City
其他城市的 胰腺癌试验
- Houston, TX61 项研究
- New York City, NY60 项研究
- Boston, MA43 项研究
- Nashville, TN39 项研究
- Los Angeles, CA35 项研究
- St. Louis, MO33 项研究
- Arlington, VA33 项研究
- Baltimore, MD31 项研究
- San Antonio, TX31 项研究
- Philadelphia, PA26 项研究
- Tampa, FL26 项研究
- Durham, NC24 项研究
Salt Lake City的其他研究
- 非小细胞肺癌31 项研究
- 癌症(所有类型)27 项研究
- 乳腺癌27 项研究
- 结直肠癌22 项研究
- 肺癌21 项研究
- 黑色素瘤21 项研究
- 多发性骨髓瘤21 项研究
- 转移性癌症20 项研究
- 卵巢癌19 项研究
- 肥胖症18 项研究
- 急性髓系白血病17 项研究
- 心力衰竭17 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。